Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies.
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies.
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study.
Active, Recruiting - Click Here
Find a Sanofi Clinical Trial
Welcome to Sanofi Clinical Trials. Their goal is to help you find out about Sanofi’s research studies into potential new treatments and vaccines. Looking for research into a specific condition? You can use the search function to find a clinical trial near you. Click Here
Here are 2 studies listed below:
Cold Agglutinin Disease Real World Evidence Registry (CADENCE)
Efficacy, Safety and Pharmacokinetics of Rilizabrutinib in Patients with Warm Autoimmue Hemolytic Anemia (wAIHA) This is a single group treatment, Phase 2 open-label, study to evaluate the efficacy, safety and pharmacokinetics of rilizabrutinib in adult patients with wAIHA.
As of September 29, 2021 Active, Not Recruiting YET
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmunce Hemolytic Anemia (wAIHA). Part A: To evaluate the safety and tolerability of subcutaneous injections of isatuximab in adults with wAIHA Part B: To evaluate the efficacy of the selected dose in adults with wAIHA
Active, Recruiting
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. The safety and scientific validity of these studies is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the CADF Foundation. Please review our Privacy and Policies for more information.
Copyright © 2022 Cold Agglutinin Disease Foundation - All Rights Reserved.
Contact Us: info@cadfadvocacy.org